Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
1.910
-0.060 (-3.05%)
At close: Feb 21, 2025, 4:00 PM
1.960
+0.050 (2.62%)
After-hours: Feb 21, 2025, 6:12 PM EST
Precigen Revenue
Precigen had revenue of $953.00K in the quarter ending September 30, 2024, a decrease of -30.89%. This brings the company's revenue in the last twelve months to $3.96M, down -41.38% year-over-year. In the year 2023, Precigen had annual revenue of $6.23M, down -76.87%.
Revenue (ttm)
$3.96M
Revenue Growth
-41.38%
P/S Ratio
123.70
Revenue / Employee
$19,619
Employees
202
Market Cap
559.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -17.73M | -55.40% |
| Dec 31, 2020 | 31.99M | -58.73M | -64.74% |
| Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PGEN News
- 5 weeks ago - Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 weeks ago - Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PRNewsWire
- 2 months ago - Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock - PRNewsWire
- 3 months ago - Precigen Reports Third Quarter 2024 Financial Results and Business Updates - PRNewsWire
- 3 months ago - Precigen to Participate in the Stifel 2024 Healthcare Conference - PRNewsWire
- 5 months ago - Precigen to Participate in the 2024 Cantor Global Healthcare Conference - PRNewsWire
- 6 months ago - Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session - Benzinga